Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest update is out from Philogen SpA ( (IT:PHIL) ).
Philogen S.p.A. recently executed a share buyback program, purchasing 3,459 shares from January 6 to January 10, 2025, at an average price of Euro 18.8393 per share, totaling Euro 65,165.27. This effort is part of an ongoing initiative that has resulted in the company acquiring 7,223 shares since the program’s inception, indicating a strategic move to potentially enhance shareholder value and improve market positioning.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology company specializing in the research and development of pharmaceutical products, primarily focusing on targeted anti-cancer drugs. The company employs unique technologies such as Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries to develop ligands for tumor targeting, aiming to deliver potent therapeutic agents specifically to tumor masses while sparing healthy tissues.
YTD Price Performance: -3.16%
Average Trading Volume: 233
Technical Sentiment Consensus Rating: Hold
Current Market Cap: €546.8M
For detailed information about PHIL stock, go to TipRanks’ Stock Analysis page.
